drugset / Trial / NCT07055568
A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer
Not yet recruiting
18 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the preliminary safety and tolerability of iNKT cell injection after infusion in each group of subjects, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for extended studies.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2027-09-30
- Completion
- 2028-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNKT | Cell therapy | 5e+07 cells | Intravenous |
| Subject | iNKT | Cell therapy | 3e+08 cells | Intravenous |